The First Approved COVID-19 Vaccines: The Road to Cancer Vaccines

Journal of International Translational Medicine Pub Date : 2022-07-01 DOI:10.3390/ijtm2030025

Leo F. Saldanha, N. Vale

{"title":"The First Approved COVID-19 Vaccines: The Road to Cancer Vaccines","authors":"Leo F. Saldanha, N. Vale","doi":"10.3390/ijtm2030025","DOIUrl":null,"url":null,"abstract":"In the past decade, mRNA vaccines have been highly discussed as a promising therapy for cancer. With the pandemic of COVID-19, some researchers redirected their studies to the development of a new vaccine for COVID-19 due to the urgent need. With the pandemic’s deceleration due to the vaccines’ success, the research and development of mRNA vaccines have turned to cancer again. Considering the new evidence and results generated by the vaccination of millions of people with mRNA vaccines, this article intends to provide a perspective on how the results from COVID-19 vaccination could now provide new insights for the development of an mRNA cancer vaccine. Many lessons were learned, and new evidence is available to re-focus and enhance the potential of the mRNA technology to cancer. Pfizer-BioNTech and Moderna’s mRNA technologies, and their significant advancements, allowed mRNA to overcome many of the challenges and blockers related to this platform in the past, now providing a new breadth of hope on using the mRNA technology to treat many diseases, namely cancer. This study also reports a better understanding of how it was possible to boost an accelerated development process of COVID-19 vaccines from a regulatory point of view. It is also relevant to consider other synergies and factors that contributed to gathering all the conditions ensuring the development of these vaccines in such a short period. Suppose the same efforts from all stakeholders could be applied to the development of new cancer vaccines, aligned now with the new scientific evidence generated from the current mRNA vaccines for COVID-19. In that case, mRNA cancer vaccines are near, and a new era for cancer treatment is about to begin.","PeriodicalId":43005,"journal":{"name":"Journal of International Translational Medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of International Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/ijtm2030025","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

Abstract

In the past decade, mRNA vaccines have been highly discussed as a promising therapy for cancer. With the pandemic of COVID-19, some researchers redirected their studies to the development of a new vaccine for COVID-19 due to the urgent need. With the pandemic’s deceleration due to the vaccines’ success, the research and development of mRNA vaccines have turned to cancer again. Considering the new evidence and results generated by the vaccination of millions of people with mRNA vaccines, this article intends to provide a perspective on how the results from COVID-19 vaccination could now provide new insights for the development of an mRNA cancer vaccine. Many lessons were learned, and new evidence is available to re-focus and enhance the potential of the mRNA technology to cancer. Pfizer-BioNTech and Moderna’s mRNA technologies, and their significant advancements, allowed mRNA to overcome many of the challenges and blockers related to this platform in the past, now providing a new breadth of hope on using the mRNA technology to treat many diseases, namely cancer. This study also reports a better understanding of how it was possible to boost an accelerated development process of COVID-19 vaccines from a regulatory point of view. It is also relevant to consider other synergies and factors that contributed to gathering all the conditions ensuring the development of these vaccines in such a short period. Suppose the same efforts from all stakeholders could be applied to the development of new cancer vaccines, aligned now with the new scientific evidence generated from the current mRNA vaccines for COVID-19. In that case, mRNA cancer vaccines are near, and a new era for cancer treatment is about to begin.

查看原文本刊更多论文

首批获批的COVID-19疫苗:通往癌症疫苗之路

在过去的十年中，mRNA疫苗作为一种有希望的癌症治疗方法被高度讨论。随着新冠肺炎大流行，一些研究人员出于迫切需要，将研究方向转向了新冠病毒疫苗的开发。由于疫苗的成功，大流行的速度有所减缓，mRNA疫苗的研究和开发再次转向癌症。考虑到数百万人接种mRNA疫苗所产生的新证据和结果，本文旨在就COVID-19疫苗接种的结果如何为mRNA癌症疫苗的开发提供新的见解提供一个视角。我们从中吸取了许多教训，并有了新的证据来重新关注和增强mRNA技术对癌症的潜力。辉瑞- biontech和Moderna的mRNA技术及其重大进步，使mRNA能够克服过去与该平台相关的许多挑战和阻滞剂，现在为使用mRNA技术治疗许多疾病(即癌症)提供了新的希望。这项研究还报告了从监管的角度更好地理解如何可能促进COVID-19疫苗的加速开发过程。还应考虑其他协同作用和因素，这些因素有助于收集确保在如此短的时间内开发出这些疫苗的所有条件。假设所有利益攸关方的同样努力可以应用于开发新的癌症疫苗，并与当前COVID-19 mRNA疫苗产生的新科学证据保持一致。在这种情况下，mRNA癌症疫苗即将问世，癌症治疗的新时代即将开始。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of International Translational Medicine MEDICINE, RESEARCH & EXPERIMENTAL-

自引率

0.00%

发文量

317

审稿时长

8 weeks

期刊介绍： Journal of International Translational Medicine (JITM, ISSN 2227-6394), founded in 2012, is an English academic journal published by Journal of International Translational Medicine Co., Ltd and sponsored by International Fderation of Translational Medicine. JITM is an open access journal freely serving to submit, review, publish, read and download full text and quote. JITM is a quarterly publication with the first issue published in March, 2013, and all articles published in English are compiled and edited by professional graphic designers according to the international compiling and editing standard. All members of the JITM Editorial Board are the famous international specialists in the field of translational medicine who come from twenty different countries and areas such as USA, Britain, France, Germany and so on.